|
EA011158B1
(ru)
*
|
2004-03-16 |
2009-02-27 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Замещённые глюкопиранозилом бензольные производные, содержащие эти соединения лекарственные средства, их применение и способ их получения
|
|
AR051446A1
(es)
*
|
2004-09-23 |
2007-01-17 |
Bristol Myers Squibb Co |
Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
|
|
JP2008524162A
(ja)
|
2004-12-16 |
2008-07-10 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
グルコピラノシル置換ベンゼン誘導体、該化合物を含む薬物、その使用及びその製造方法
|
|
JP5264183B2
(ja)
*
|
2005-02-23 |
2013-08-14 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
グルコピラノシル置換（（ヘテロ）アリールエチニル−ベンジル）−ベンゼン誘導体及びナトリウム依存性グルコース共輸送体２（ｓｇｌｔ２）インヒビターとしてのそれらの使用
|
|
WO2006108842A1
(en)
*
|
2005-04-15 |
2006-10-19 |
Boehringer Ingelheim International Gmbh |
Glucopyranosyl-substituted (heteroaryloxy-benzyl)-benzene derivatives as sglt inhibitors
|
|
US7723309B2
(en)
|
2005-05-03 |
2010-05-25 |
Boehringer Ingelheim International Gmbh |
Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
|
|
UA91546C2
(uk)
|
2005-05-03 |
2010-08-10 |
Бьорінгер Інгельхайм Інтернаціональ Гмбх |
КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
|
|
US7772191B2
(en)
|
2005-05-10 |
2010-08-10 |
Boehringer Ingelheim International Gmbh |
Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
|
|
EP1910390B1
(en)
|
2005-07-27 |
2010-05-19 |
Boehringer Ingelheim International GmbH |
Glucopyranosyl-substituted ((hetero)cycloalyklethynyl-benzyl)-benzene derivatives and use thereof as sodium-dependent glucose cotransporter (sglt) inhibitors
|
|
JP5175191B2
(ja)
|
2005-08-30 |
2013-04-03 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
グリコピラノシル置換ベンジルベンゼン誘導体、該化合物を含有する医薬品及びその使用と製造方法
|
|
BRPI0615882A2
(pt)
*
|
2005-09-08 |
2011-05-31 |
Boehringer Ingelheim Int |
formas cristalinas de 1-cloro-4-(beta-d-glicopiranos-1-il)-2-(4-etinil-benzil)- benzeno, métodos para sua preparação e o uso para preparar medicamentos do mesmo
|
|
AR056195A1
(es)
*
|
2005-09-15 |
2007-09-26 |
Boehringer Ingelheim Int |
Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos
|
|
CA2634701C
(en)
*
|
2005-12-21 |
2014-07-29 |
Decode Genetics Ehf |
Biaryl substituted nitrogen containing heterocycle inhibitors of lta4h for treating inflammation
|
|
AR059489A1
(es)
*
|
2006-02-15 |
2008-04-09 |
Boehringer Ingelheim Vetmed |
Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
|
|
PE20080697A1
(es)
|
2006-05-03 |
2008-08-05 |
Boehringer Ingelheim Int |
Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
|
|
PE20080251A1
(es)
|
2006-05-04 |
2008-04-25 |
Boehringer Ingelheim Int |
Usos de inhibidores de dpp iv
|
|
CA2656847A1
(en)
|
2006-08-15 |
2008-02-21 |
Boehringer Ingelheim International Gmbh |
Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as sglt inhibitors and process for their manufacture
|
|
CA2664095A1
(en)
*
|
2006-09-21 |
2008-03-27 |
Boehringer Ingelheim International Gmbh |
Glucopyranosyl-substituted difluorobenzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
|
|
US8283326B2
(en)
|
2006-10-27 |
2012-10-09 |
Boehringer Ingelheim International Gmbh |
Crystalline form of 4-(beta-D-glucopyranos-1-yl)-1-methyl-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
|
|
AR063569A1
(es)
|
2006-11-06 |
2009-02-04 |
Boehringer Ingelheim Int |
Derivados de benzil- benzonitrilo sustituidos con glucopiranosilo medicamentos que contienen a compuestos de este tipo su uso u procedimiento para su fabricacion
|
|
JP2010516742A
(ja)
|
2007-01-26 |
2010-05-20 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
神経変性疾患を予防及び治療する方法
|
|
JP2010519273A
(ja)
|
2007-02-21 |
2010-06-03 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
四置換グルコピラノシル化ベンゼン誘導体、このような化合物を含む薬物、それらの使用及びそれらの製造方法
|
|
EP2064222B1
(en)
*
|
2007-04-02 |
2014-05-07 |
Theracos, Inc. |
Benzylic glycoside derivatives and methods of use
|
|
PE20090938A1
(es)
|
2007-08-16 |
2009-08-08 |
Boehringer Ingelheim Int |
Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
|
|
AU2008288770B2
(en)
*
|
2007-08-23 |
2014-06-12 |
Theracosbio, Llc |
Benzylbenzene derivatives and methods of use
|
|
US8648085B2
(en)
*
|
2007-11-30 |
2014-02-11 |
Boehringer Ingelheim International Gmbh |
1, 5-dihydro-pyrazolo (3, 4-D) pyrimidin-4-one derivatives and their use as PDE9A mudulators for the treatment of CNS disorders
|
|
UA101004C2
(en)
|
2007-12-13 |
2013-02-25 |
Теракос, Инк. |
Derivatives of benzylphenylcyclohexane and use thereof
|
|
UA105362C2
(en)
|
2008-04-02 |
2014-05-12 |
Бьорингер Ингельхайм Интернациональ Гмбх |
1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
|
|
MX2011001855A
(es)
*
|
2008-08-22 |
2011-03-24 |
Theracos Inc |
Procesos para la preparacion de inhibidores de sglt2.
|
|
ES2380408T3
(es)
*
|
2008-08-28 |
2012-05-11 |
Pfizer Inc. |
Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol
|
|
CN102143965A
(zh)
|
2008-09-08 |
2011-08-03 |
贝林格尔.英格海姆国际有限公司 |
吡唑并嘧啶酮及其在治疗中枢神经系统疾病中的用途
|
|
AU2016213789B2
(en)
*
|
2009-02-13 |
2018-01-18 |
Boehringer Ingelheim International Gmbh |
SGLT-2 inhibitor for treating type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance or hyperglycemia
|
|
US20110014284A1
(en)
|
2009-02-13 |
2011-01-20 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
|
|
UY32427A
(es)
|
2009-02-13 |
2010-09-30 |
Boheringer Ingelheim Internat Gmbh |
Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma
|
|
KR20110118668A
(ko)
*
|
2009-02-13 |
2011-10-31 |
베링거 인겔하임 인터내셔날 게엠베하 |
１형 당뇨병, ２형 당뇨병, 내당능 장애 또는 고혈당증을 치료하기 위한 ｓｇｌｔ２ 억제제
|
|
MX339194B
(es)
|
2009-02-13 |
2016-05-16 |
Boehringer Ingelheim Int |
Composicion farmaceutica que comprende un inhibidor de sglt2, un inhibidor de dpp-iv y opcionalmente otro agente antidiabetico, y usos de la misma.
|
|
UY32531A
(es)
|
2009-03-31 |
2010-10-29 |
Boehringer Ingelheim Int |
Nuevos compuestos para el tratamiento de trastornos del snc
|
|
AR077859A1
(es)
*
|
2009-08-12 |
2011-09-28 |
Boehringer Ingelheim Int |
Compuestos para el tratamiento de trastornos del snc
|
|
DK2486029T3
(en)
*
|
2009-09-30 |
2015-08-24 |
Boehringer Ingelheim Int |
Methods of making of glucopyranosyl-substituted benzyl-benzene derivatives.
|
|
ES2596202T3
(es)
|
2009-09-30 |
2017-01-05 |
Boehringer Ingelheim International Gmbh |
Método para la preparación de una forma cristalina de 1-cloro-4-(ß-D-glucopiranos-1-il)-2-[4-((S)-tetrahidrofuran-3-iloxi)-bencil]-benceno
|
|
US10610489B2
(en)
|
2009-10-02 |
2020-04-07 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
|
|
US8669380B2
(en)
|
2009-11-02 |
2014-03-11 |
Pfizer Inc. |
Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
|
|
AR079438A1
(es)
|
2009-12-09 |
2012-01-25 |
Panacea Biotec Ltd |
Derivados de azucar, composiciones farmaceuticas y sus usos
|
|
JP2013523681A
(ja)
|
2010-03-30 |
2013-06-17 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Ｓｇｌｔ２インヒビター及びｐｐａｒ−ガンマアゴニストを含む医薬組成物並びにその使用
|
|
WO2011153712A1
(en)
|
2010-06-12 |
2011-12-15 |
Theracos, Inc. |
Crystalline form of benzylbenzene sglt2 inhibitor
|
|
PT2595980E
(pt)
|
2010-07-22 |
2014-11-27 |
Gilead Sciences Inc |
Métodos e compostos para tratar infeções pelo vírus da família paramyxoviridae
|
|
BR112013003097B1
(pt)
|
2010-08-12 |
2021-03-16 |
Boehringer Ingelheim International Gmbh |
6-cicloalquil-pirazolopirimidinonas e composição farmacêutica
|
|
JP2013224263A
(ja)
*
|
2010-08-19 |
2013-10-31 |
Taisho Pharmaceutical Co Ltd |
４−イソプロピルフェニルグルシトール化合物
|
|
WO2012041898A1
(en)
|
2010-09-29 |
2012-04-05 |
Celon Pharma Sp. Z O.O. |
Combination of sglt2 inhibitor and a sugar compound for the treatment of diabetes
|
|
CA2813671A1
(en)
|
2010-11-02 |
2012-05-10 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical combinations for the treatment of metabolic disorders
|
|
US20120283169A1
(en)
|
2010-11-08 |
2012-11-08 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
|
US20130035281A1
(en)
|
2011-02-09 |
2013-02-07 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
|
US8809345B2
(en)
|
2011-02-15 |
2014-08-19 |
Boehringer Ingelheim International Gmbh |
6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
|
|
AR085689A1
(es)
|
2011-03-07 |
2013-10-23 |
Boehringer Ingelheim Int |
Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2
|
|
EP2703396B1
(en)
*
|
2011-04-25 |
2016-06-22 |
Beijing Prelude Pharm. Sci.& Tech. Co., Ltd. |
Inhibitor of sodium-dependent glucose transport protein and preparation method therefor and use thereof
|
|
WO2012163990A1
(en)
|
2011-06-03 |
2012-12-06 |
Boehringer Ingelheim International Gmbh |
Sglt-2 inhibitors for treating metabolic disorders in patients treated with neuroleptic agents
|
|
US20130035298A1
(en)
|
2011-07-08 |
2013-02-07 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
|
WO2013038429A2
(en)
|
2011-09-13 |
2013-03-21 |
Panacea Biotec Ltd. |
Novel sglt inhibitors
|
|
US9555001B2
(en)
|
2012-03-07 |
2017-01-31 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition and uses thereof
|
|
US9192617B2
(en)
|
2012-03-20 |
2015-11-24 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
|
WO2013152476A1
(en)
|
2012-04-10 |
2013-10-17 |
Theracos, Inc. |
Process for the preparation of benzylbenzene sglt2 inhibitors
|
|
EP2846797A1
(en)
|
2012-05-09 |
2015-03-18 |
Boehringer Ingelheim International GmbH |
Pharmaceutical combinations for the treatment of metabolic disorders
|
|
ES2959444T3
(es)
|
2013-04-04 |
2024-02-26 |
Boehringer Ingelheim Vetmedica Gmbh |
Tratamiento de trastornos metabólicos en animales equinos
|
|
CA2812519A1
(en)
|
2013-04-05 |
2014-10-05 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
|
HRP20190101T1
(hr)
|
2013-04-05 |
2019-03-08 |
Boehringer Ingelheim International Gmbh |
Terapeutske uporabe empagliflozina
|
|
US11813275B2
(en)
|
2013-04-05 |
2023-11-14 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
|
US20140303097A1
(en)
|
2013-04-05 |
2014-10-09 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
|
PL2986304T3
(pl)
|
2013-04-18 |
2022-05-02 |
Boehringer Ingelheim International Gmbh |
Kompozycja farmaceutyczna, sposoby leczenia i jej zastosowania
|
|
CN104447893B
(zh)
*
|
2013-09-25 |
2018-01-23 |
广东东阳光药业有限公司 |
吡喃葡萄糖基衍生物及其在医药上的应用
|
|
WO2015051484A1
(en)
|
2013-10-12 |
2015-04-16 |
Theracos, Inc. |
Preparation of hydroxy-benzylbenzene derivatives
|
|
EP3082829B1
(en)
|
2013-12-17 |
2021-02-17 |
Boehringer Ingelheim Vetmedica GmbH |
Sglt2 inhibitors for the treatment of metabolic disorders in feline animals
|
|
EA032558B1
(ru)
|
2014-01-23 |
2019-06-28 |
Бёрингер Ингельхайм Ветмедика Гмбх |
Лечение метаболических расстройств у представителей собачьих
|
|
DK3721882T3
(da)
*
|
2014-04-01 |
2024-10-21 |
Boehringer Ingelheim Vetmedica Gmbh |
Behandling af hypofyse pars intermedia-dysfunktion hos hestedyr
|
|
KR102539788B1
(ko)
|
2014-09-25 |
2023-06-07 |
베링거잉겔하임베트메디카게엠베하 |
말과 동물의 대사 장애를 예방하기 위한 sglt2 억제제와 도파민 작용제의 병용 치료
|
|
TWI698444B
(zh)
|
2014-10-29 |
2020-07-11 |
美商基利科學股份有限公司 |
製備核糖苷的方法
|
|
CN107683135A
(zh)
|
2015-03-09 |
2018-02-09 |
因特克林医疗有限公司 |
用于治疗非酒精性脂肪肝疾病和/或脂肪营养不良的方法
|
|
MX389367B
(es)
|
2015-08-27 |
2025-03-20 |
Boehringer Ingelheim Vetmedica Gmbh |
Composiciones farmaceuticas liquidas que comprenden inhibidores de sglt-2.
|
|
DK3349758T3
(da)
|
2015-09-16 |
2022-06-13 |
Gilead Sciences Inc |
Fremgangsmåder til behandling af arenaviridae-virusinfektioner
|
|
EP3362055B1
(en)
|
2015-10-15 |
2023-01-18 |
Boehringer Ingelheim International GmbH |
Sglt-2 inhibitor for use in the treatment of a metabolic myopathy
|
|
WO2018087132A1
(en)
|
2016-11-10 |
2018-05-17 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
|
CN110869028B
(zh)
|
2017-03-14 |
2023-01-20 |
吉利德科学公司 |
治疗猫冠状病毒感染的方法
|
|
AU2018249822A1
(en)
|
2017-04-03 |
2019-10-31 |
Coherus Biosciences Inc. |
PPArgamma agonist for treatment of progressive supranuclear palsy
|
|
EP4219513A1
(en)
|
2017-05-01 |
2023-08-02 |
Gilead Sciences, Inc. |
Crystalline form of (s)-2-ethylbutyl 2-(((s)-(((2r,3s,4r,5r)-5-(4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran2-yl)methoxy)(phenoxy) phosphoryl)amino)propanoate
|
|
CN111093627B
(zh)
|
2017-07-11 |
2024-03-08 |
吉利德科学公司 |
用于治疗病毒感染的包含rna聚合酶抑制剂和环糊精的组合物
|
|
KR102204439B1
(ko)
|
2018-05-14 |
2021-01-18 |
에이치케이이노엔 주식회사 |
Sglt-2 억제제 및 dpp-iv 억제제를 포함하는 약제학적 조성물
|
|
WO2020039394A1
(en)
|
2018-08-24 |
2020-02-27 |
Novartis Ag |
New drug combinations
|
|
CN114585358B
(zh)
|
2019-07-26 |
2023-11-10 |
东宝紫星(杭州)生物医药有限公司 |
一种SGLTs/DPP4抑制剂及其应用
|
|
BR112022010385A2
(pt)
|
2019-11-28 |
2022-08-23 |
Boehringer Ingelheim Vetmedica Gmbh |
Uso de inibidores de sglt-2 na secagem de mamíferos não humanos
|
|
KR20220132608A
(ko)
|
2020-01-27 |
2022-09-30 |
길리애드 사이언시즈, 인코포레이티드 |
SARS CoV-2 감염증을 치료하기 위한 방법
|
|
KR20220143732A
(ko)
|
2020-02-17 |
2022-10-25 |
베링거잉겔하임베트메디카게엠베하 |
고양이과에서 심장 질환을 예방 및/또는 치료하기 위한 sglt-2 억제제의 사용
|
|
EP4114385A1
(en)
|
2020-03-06 |
2023-01-11 |
Vertex Pharmaceuticals Incorporated |
Methods of treating apol-1 dependent focal segmental glomerulosclerosis
|
|
TWI785528B
(zh)
|
2020-03-12 |
2022-12-01 |
美商基利科學股份有限公司 |
1’-氰基核苷之製備方法
|
|
JP7482250B2
(ja)
|
2020-04-06 |
2024-05-13 |
ギリアード サイエンシーズ， インコーポレイテッド |
１’－シアノ置換カルバヌクレオシド類似体の吸入製剤
|
|
EP4157272B1
(en)
|
2020-05-29 |
2025-07-02 |
Gilead Sciences, Inc. |
Remdesivir for the treatment of viral infections
|
|
IL299202A
(en)
|
2020-06-24 |
2023-02-01 |
Gilead Sciences Inc |
1'-cyano nucleoside analogs and uses thereof
|
|
US11926645B2
(en)
|
2020-08-27 |
2024-03-12 |
Gilead Sciences, Inc. |
Compounds and methods for treatment of viral infections
|
|
WO2022051316A1
(en)
|
2020-09-03 |
2022-03-10 |
Coherus Biosciences, Inc. |
Fixed dose combinations of chs-131 and a sglt-2 inhibitor
|
|
US20240398845A1
(en)
|
2021-07-28 |
2024-12-05 |
Boehringer Ingelheim Vetmedica Gmbh |
Use of sglt-2 inhibitors for the prevention and/or treatment of cardiac diseases in non-human mammals excluding felines, in particular canines
|
|
EP4376830A1
(en)
|
2021-07-28 |
2024-06-05 |
Boehringer Ingelheim Vetmedica GmbH |
Use of sglt-2 inhibitors for the prevention and/or treatment of renal diseases in non-human mammals
|
|
CA3242880A1
(en)
|
2021-12-30 |
2023-07-06 |
Newamsterdam Pharma B.V. |
COMBINATION OF OBITECRAPIB AND SGLT2 INHIBITOR
|
|
KR20240154647A
(ko)
|
2022-03-02 |
2024-10-25 |
길리애드 사이언시즈, 인코포레이티드 |
바이러스성 감염 치료를 위한 화합물 및 방법
|
|
JP2025516857A
(ja)
|
2022-05-25 |
2025-05-30 |
ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー |
Ｓｇｌｔ－２阻害薬を含む水性医薬組成物
|
|
EP4547665A1
(en)
|
2022-06-30 |
2025-05-07 |
Gilead Sciences, Inc. |
Solid forms of a nucleoside analogue and uses thereof
|
|
US12357577B1
(en)
|
2024-02-02 |
2025-07-15 |
Gilead Sciences, Inc. |
Pharmaceutical formulations and uses thereof
|
|
US20240307628A1
(en)
|
2023-03-06 |
2024-09-19 |
Boehringer Ingelheim Vetmedica Gmbh |
Systems and methods for delivery of liquid pharmaceutical compositions in particular comprising one or more sglt-2 inhibitor(s)
|
|
TW202446389A
(zh)
|
2023-04-24 |
2024-12-01 |
荷蘭商新阿姆斯特丹製藥公司 |
非晶形奧比特拉(obicetrapib)與sglt2抑制劑之組合
|
|
AU2024276892A1
(en)
|
2023-05-24 |
2025-10-16 |
Boehringer Ingelheim Vetmedica Gmbh |
Combination treatment and/or prevention of cardiac diseases in non-human mammals comprising one or more sglt-2 inhibitors and pimobendan and/or telmisartan
|
|
CN121175053A
(zh)
|
2023-05-24 |
2025-12-19 |
勃林格殷格翰动物保健有限公司 |
包含一或多种sglt-2抑制剂及替米沙坦的非人类哺乳动物中肾脏疾病和/或高血压的组合治疗和/或预防
|